RxDoctor Payments Data

Lindsay Jones, APRN

Family · Jeffersonville, INNPI 1336615384

Payments from drug & device makers

$1,879in general payments, 2019–2025

Across 115 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • Novo Nordisk$323
  • Pfizer$161
  • Exact Sciences$110
  • AstraZeneca$103
  • GSK$87
  • plus $593 from 21 others

What the payments were for

  • Food & beverage$1,879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,879 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$134,648
Medicare patients
335
Services billed
1,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$43,601
JardianceEmpagliflozin31$38,796
TrulicityDulaglutide17$33,868
OzempicSemaglutide27$30,666
MounjaroTirzepatide27$28,035
MyrbetriqMirabegron24$22,625
WegovySemaglutide13$19,646
JanuviaSitagliptin Phosphate18$18,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,150
Mirabegron ErMirabegron11$8,667
Breo ElliptaFluticasone/Vilanterol22$8,628
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$7,551
VascepaIcosapent Ethyl13$6,578
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$5,427
SynthroidLevothyroxine Sodium83$4,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$65$61,90344 claims
Novo NordiskOzempic, Wegovy$323$50,31240 claims
Boehringer IngelheimJardiance, Stiolto Respimat$49$46,34847 claims
PfizerEliquis$161$43,60145 claims
Astellas Pharma US IncMyrbetriq$32$22,62524 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$87$21,21848 claims
MerckJanuvia$16$18,42218 claims
AbbVieSynthroid$502$4,63383 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$3,234356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →